The supplemental disclosure is a routine response to deal litigation and does not alter the merger consideration or likely timeline. The July 23 special meeting vote is the next key catalyst. Traders should monitor for any court ruling on the preliminary injunction motion, but the company's voluntary supplement reduces the risk of delay. Current market price relative to $13.50 deal price implies a narrow arbitrage spread reflecting residual closing risk.
Price Chart
Executive Summary
Organon filed an 8-K supplementing its definitive proxy statement for the pending Sun Pharma merger to address a shareholder lawsuit alleging inadequate disclosures. The company voluntarily added management projections showing 2026E revenue of $6.252B and Adjusted EBITDA of $1.894B, along with the $700M synergy estimate that was previously presented to Sun Pharma. The special meeting is scheduled for July 23, 2026; the company denies the claims but seeks to avoid any risk of delay.
Key Facts
- Shareholder lawsuit filed July 6, 2026 in New Jersey Superior Court alleging proxy statement disclosures were incomplete and misleading
- Company voluntarily supplements proxy with detailed financial projections: 2026E revenue $6,252M, 2026E Adjusted EBITDA $1,894M, 2026E Unlevered FCF $1,010M
- Synergy estimate of approximately $700 million in aggregate identified during January 2026 discussions with Sun Pharma
- Net debt as of March 31, 2026 was $7,530M; Adjusted LTM EBITDA was $1,832M; fully diluted shares outstanding ~284.9M
- Special stockholder meeting to vote on merger remains scheduled for July 23, 2026
Financial Impact
No change to deal terms or consideration; incremental disclosure of management projections and synergy estimates with total revenue projections ranging ~$6.25B-$6.82B through 2030
Risk Factors
- Court could still grant preliminary injunction delaying the stockholder vote or requiring further disclosures
- Additional shareholder lawsuits could arise before the special meeting
- Deal completion remains subject to stockholder approval and regulatory clearances
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-307767 |
| Document: 0001193125-26-307767-index-headers.html | 0001193125-26-307767 |
| Document: 0001193125-26-307767-index.html | 0001193125-26-307767 |
| Document: 0001193125-26-307767.txt | 0001193125-26-307767 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 18, 2026 9w ago | Institutional Cluster | $13.68 | awaiting T+60 | — | $13.74 (−0.44%) |
Jul 31, 2026 12w ago | 8-K | $13.55 $13.74 | ▼ −1.40% | ▲ +1.05% | $13.74 (−1.40%) |
Jul 17, 2026 14w ago | 8-K | $13.49 $13.77 | ▲ +2.08% | ▼ −2.76% | $13.74 (+1.85%) |
Jun 17, 2026 18w ago | DEFM14A | $13.42 $13.64 | ▲ +1.64% | ▼ −1.51% | $13.74 (+2.38%) |
Jun 11, 2026 19w ago | DEFA14A | $13.45 $13.78 | ▲ +2.45% | ▼ −1.94% | $13.74 (+2.16%) |
Jun 1, 2026 21w ago | PREM14A | $13.37 $13.75 | ▲ +2.84% | ▲ +1.87% | $13.74 (+2.81%) |
Apr 30, 2026 25w ago | DEFA14A | $13.25 $13.52 | ▲ +2.08% | ▼ −0.74% | $13.74 (+3.74%) |
Apr 30, 2026 25w ago | 8-K | $13.25 $13.52 | ▼ −2.08% | ▲ +0.74% | $13.74 (−3.74%) |
Apr 27, 2026 26w ago | DEFA14A | $13.32 $13.56 | ▲ +1.84% | ▼ −1.88% | $13.74 (+3.19%) |
Apr 27, 2026 26w ago | DEFA14A | $13.32 $13.56 | ▲ +1.84% | ▼ −1.88% | $13.74 (+3.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers